Page 154 - 2019_06-Haematologica-web

M. Robin et al.
agnogenic myeloid metaplasia: a European
Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93(9):2831–2838.
13. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell trans- plantation for myelofibrosis. Blood. 2003;102(12):3912–3918.
14. Kerbauy DMB, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as cura- tive therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355–365.
15. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell trans- plantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514–1522.
16. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell trans- plantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331–339.
17. Rondelli D, Goldberg JD, Isola L, et al. MPD- RC 101 prospective study of reduced-inten- sity allogeneic hematopoietic stem cell transplantation in patients with myelofibro- sis. Blood. 2014;124(7):1183–1191.
18. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicen- ter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114 (26):5264–5270.
19. Kröger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J
Med. 2016;374(1):43–53.
20. Gooley TA, Leisenring W, Crowley J, Storer
BE. Estimation of failure probabilities in the presence of competing risks: new represen- tations of old estimators. Stat Med. 1999;18(6):695–706.
21. Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography. 1979;16(3):439–454.
22. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibro- sis. Biol Blood Marrow Transplant. 2010;16(3):358–367.
23. Kristinsson SY, Björkholm M, Hultcrantz M, Derolf ÅR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897–2903.
24. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neo- plasms. Haematologica. 2010;95(7):1216– 1220.
25. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombo- cythemia, polycythemia vera, and myelofi- brosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219–3225.
26. Hasselbalch HC, Bjørn ME. MPNs as inflam- matory diseases: the evidence, conse- quences, and perspectives. Mediators Inflamm. 2015;2015:102476.
27. Kröger N, Zabelina T, Alchalby H, et al. Dynamic of bone marrow fibrosis regres- sion predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2014;20(6):812– 815.
28. Hussein K, Stucki-Koch A, Alchalby H, Triviai I, Kröger N, Kreipe H. Cytokine expression pattern in bone marrow
microenvironment after allogeneic stem cell transplantation in primary myelofibrosis. Biol Blood Marrow Transplant. 2016;22(4): 644–650.
29. Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res. 2014;2(5):393–398.
30. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
31. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus- host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942– 2947.
32. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophy- laxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864.
33. Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplanta- tion from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173.
34. Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft- versus-host disease-free survival in patients undergoing HLA-matched unrelat- ed myeloablative hematopoietic cell trans- plantation. J Clin Oncol. 2017;35(36): 4003– 4011.
1236
haematologica | 2019; 104(6)